Hyperkalemia Management

Introduction to Hyperkalemia

The American College of Cardiology recommends that hyperkalemia (serum potassium >5.0-5.5 mEq/L) is the most important and potentially lethal electrolyte disorder related to residual renal function loss, with the risk of hyperkalemia increasing progressively as the glomerular filtration rate (GFR) decreases, particularly when the GFR falls below 15 mL/min per 1.73 m² 1, 2
The National Kidney Foundation states that the loss of renal function compromises the kidneys' ability to excrete potassium, which normally accounts for 90% of the body's total potassium excretion 1

The American Heart Association notes that patients with chronic kidney disease have multiple risk factors that cluster and amplify the risk of hyperkalemia, including the use of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors) in patients with GFR <60 mL/min per 1.73 m², which increases progressively with decreasing GFR 2
The European Society of Cardiology recommends that diabetes mellitus, especially in diabetic nephropathy with hyporeninemic hypoaldosteronism, is a risk factor for hyperkalemia 1
The American College of Cardiology states that heart failure increases the risk of hyperkalemia both due to the disease and the medications used 1
The National Kidney Foundation notes that additional medications, such as heparin, β-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, trimethoprim, pentamidine, and potassium-sparing diuretics, can increase the risk of hyperkalemia 1

The American Heart Association recommends that the frequency of monitoring should be based on patient comorbidities and medications, particularly in those with high risk of hyperkalemia 1, 2
The European Society of Cardiology states that in patients with chronic kidney disease and/or chronic heart failure who receive RAAS inhibitors, the risk factors for recurrent hyperkalemia within 6 months include initial moderate to severe hyperkalemia (≥5.6 mEq/L), low GFR (<45 mL/min per 1.73 m²), diabetes, and use of spironolactone 2
The American College of Cardiology recommends that severe hyperkalemia (>6.0 mmol/L) requires continuous cardiac monitoring and urgent treatment, including stabilization of the myocardial membrane with calcium chloride or calcium gluconate, shifting of potassium into cells with insulin/glucose, bicarbonate, and albuterol, and promotion of potassium excretion with diuretics, ion exchange resins, or dialysis 3

The American College of Cardiology and other guideline societies recommend that hyperkalemia (serum potassium >5.0-5.5 mEq/L) be considered a potentially life-threatening medical emergency that requires close monitoring and aggressive management in patients with renal dysfunction 4, 5

Up to 65% of hospitalized patients with chronic kidney disease experience electrolyte disorders, particularly those who are critically ill, with additional risk factors including diabetes mellitus, heart failure, and the use of renin-angiotensin-aldosterone system inhibitors 4, 5

Hyperphosphatemia can occur due to reduced renal excretion of phosphate 5
Hypocalcemia can occur secondary to hyperphosphatemia and alterations in vitamin D metabolism 5
Hyponatremia can occur due to free water retention 5, 6, 7
Metabolic acidosis can occur due to the inability to excrete acids 5

The American Heart Association recommends routine monitoring of serum electrolytes and renal function in all patients with renal insufficiency, with the frequency of monitoring individualized based on the patient's condition 6, 7
More frequent monitoring is recommended for patients with chronic kidney disease, diabetes, heart failure, or a history of hyperkalemia 4
Close monitoring is especially recommended for patients receiving renin-angiotensin-aldosterone system inhibitors 4, 7

The initial management of hyperkalemia includes the use of potassium-binding agents (such as patiromer or sodium zirconium cyclosilicate) for both acute and chronic hyperkalemia 4

Severe hyperkalemia (>6.0 mmol/L) requires continuous cardiac monitoring and urgent treatment with insulin/glucose, calcium, and potentially dialysis 4, 5
Electrocardiographic changes (peaked T waves, prolonged PR interval, widened QRS complex) typically do not manifest until potassium levels exceed 6.5 mmol/L 8